PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275 · see citing works

Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency

Lucas, C. L., Kuehn, H. S., Zhao, F. R., Niemela, J. E., Deenick, E. K., Palendira, U., Avery, D. T., Moens, L., Cannons, J. L., Biancalana, M., et al. (2013) · Nature Immunology · doi:10.1038/ni.2771 · Cited by 677 · see citing works

EF-hand calcium-binding proteins

Lewit‐Bentley, A., & Réty, S. (2000) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(00)00142-1 · Cited by 568 · see citing works

<i>BTK</i> ^C481S -Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

Woyach, J. A., Ruppert, A. S., Guinn, D., Lehman, A., Blachly, J. S., Lozanski, A., Heerema, N. A., Zhao, W., Coleman, J., Jones, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.2282 · Cited by 484 · see citing works

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

Burger, J. A., Landau, D. A., Taylor-Weiner, A., Bozic, I., Zhang, H., Sarosiek, K., Wang, L., Stewart, C., Fan, J., Hoellenriegel, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11589 · Cited by 345 · see citing works

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Ahn, I. E., Underbayev, C., Albitar, A., Herman, S. E. M., Tian, X., Maric, I., Arthur, D. C., Wake, L., Pittaluga, S., Yuan, C. M., et al. (2017) · Blood · doi:10.1182/blood-2016-06-719294 · Cited by 341 · see citing works

Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Furman, R. R., Cheng, S., Lu, P., Setty, M., Perez, A. R., Guo, A., Racchumi, J., Xu, G., Wu, H., Ma, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1402716 · Cited by 300 · see citing works

BLNK

Kurosaki, T., & Tsukada, S. (2000) · Immunity · doi:10.1016/s1074-7613(00)80153-3 · Cited by 223 · see citing works

Electrostatic Control of the Membrane Targeting of C2 Domains

Murray, D., & Honig, B. H. (2002) · Molecular Cell · doi:10.1016/s1097-2765(01)00426-9 · Cited by 223 · see citing works

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Liu, T.-M., Woyach, J. A., Zhong, Y., Lozanski, A., Lozanski, G., Dong, S., Strattan, E., Lehman, A., Zhang, X., Jones, J. A., et al. (2015) · Blood · doi:10.1182/blood-2015-02-626846 · Cited by 178 · see citing works

Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations

Johnson, A. R., Kohli, P. B., Katewa, A., Gogol, E., Belmont, L. D., Choy, R., Penuel, E., Burton, L., Eigenbrot, C., Yu, C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00480 · Cited by 137 · see citing works

Dysfunction of phospholipase Cγ in immune disorders and cancer

Koss, H., Bunney, T. D., Behjati, S., & Katan, M. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.09.004 · Cited by 115 · see citing works

Structural and Functional Integration of the PLCγ Interaction Domains Critical for Regulatory Mechanisms and Signaling Deregulation

Bunney, T. D., Esposito, D., Mas-Droux, C., Lamber, E., Baxendale, R. W., Martins, M., Cole, A., Svergun, D., Driscoll, P. C., & Katan, M. (2012) · Structure · doi:10.1016/j.str.2012.09.005 · Cited by 88 · see citing works

Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array

García‐Sánz, R., Corchete, L. A., Alcoceba, M., Chillón, C., Jiménez, C., Prieto, I., García‐Álvarez, M., Puig, N., Rapado, I., Barrio, S., et al. (2016) · Hematological Oncology · doi:10.1002/hon.2337 · Cited by 28 · see citing works

Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors

Chan, K. L., Blombery, P. A., Jones, K. L., Lade, S., Carney, D. A., Tran, H., Seymour, J. F., & Tam, C. S. L. (2016) · British Journal of Haematology · doi:10.1111/bjh.14062 · Cited by 14 · see citing works

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

Jones, J. A., Mato, A. R., Wierda, W. G., Davids, M. S., Choi, M., Cheson, B. D., Furman, R. R., Lamanna, N., Barr, P. M., Zhou, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30909-9 · Cited by 383 · see citing works

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

Reiff, S. D., Mantel, R., Smith, L. L., Greene, J. T., Muhowski, E. M., Fabian, C. A., Goettl, V. M., Tran, M., Harrington, B. K., Rogers, K. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1409 · Cited by 165 · see citing works

The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration

Jackson, J. T., Mulazzani, E., Nutt, S. L., & Masters, S. L. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100905 · Cited by 113 · see citing works

Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia

Rogers, K. A., Thompson, P. A., Allan, J. N., Coleman, M., Sharman, J. P., Cheson, B. D., Jones, D., Izumi, R. E., Frigault, M. M., Quah, C. S., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.272500 · Cited by 112 · see citing works

Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor–resistant chronic lymphocytic leukemia with disease progression and Richter transformation

Kanagal‐Shamanna, R., Jain, P., Patel, K. P., Routbort, M., Bueso‐Ramos, C., Alhalouli, T., Khoury, J. D., Luthra, R., Ferrajoli, A., Keating, M., et al. (2019) · Cancer · doi:10.1002/cncr.31831 · Cited by 98 · see citing works

Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas

George, B., Chowdhury, S. M., Hart, A., Sircar, A., Singh, S. K., Nath, U. K., Mamgain, M., Singhal, N. K., Sehgal, L., & Jain, N. K. (2020) · Cancers · doi:10.3390/cancers12051328 · Cited by 96 · see citing works

Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study

Shadman, M. S., Flinn, I. W., Levy, M. Y., Porter, R. F., Burke, J. M., Zafar, S. F., Misleh, J. G., Kingsley, E. C., Yimer, H. A., Freeman, B., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00320-9 · Cited by 95 · see citing works

Phospholipase C families: Common themes and versatility in physiology and pathology

Katan, M., & Cockcroft, S. (2020) · Progress in Lipid Research · doi:10.1016/j.plipres.2020.101065 · Cited by 89 · see citing works

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

Naeem, A., Utro, F., Wang, Q., Cha, J., Vihinen, M., Martindale, S., Zhou, Y., Ren, Y., Tyekucheva, S., Kim, A. S., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008447 · Cited by 87 · see citing works

A pan-cancer-bioinformatic-based literature review of TRPM7 in cancers

Liu, H., Dilger, J. P., & Lin, J. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108302 · Cited by 87 · see citing works

Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies

Ondrišová, L., & Mráz, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.591577 · Cited by 76 · see citing works

AreBTKandPLCG2mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?

Lampson, B. L., & Brown, J. R. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1435268 · Cited by 74 · see citing works

PLCG2-associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants

Baysac, K., Sun, G., Nakano, H., Schmitz, E. G., Cruz, A. C., Fisher, C., Bailey, A. C., Abbott, J. K., Aldave Becerra, J. C., Allenspach, E. J., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.08.036 · Cited by 63 · see citing works

Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents

Sedlaříková, L., Petráčková, A., Papajík, T., Turcsányi, P., & Kriegová, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00894 · Cited by 63 · see citing works

Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Shaffer, A. L., Phelan, J. D., Wang, J. Q., Huang, D., Wright, G. W., Kasbekar, M., Choi, J., Young, R. M., Webster, D. E., Yang, Y., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0063 · Cited by 62 · see citing works

HIF-1α is over-expressed in leukemic cells from TP53 -disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia

Griggio, V., Vitale, C., Todaro, M., Riganti, C., Kopecka, J., Salvetti, C., Bomben, R., Bo, M. D., Magliulo, D., Rossi, D., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.217430 · Cited by 57 · see citing works

EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma

Liu, Y., Kimpara, S., Hoang, N. M., Daenthanasanmak, A., Li, Y., Lü, L., Ngo, V. N., Bates, P. D., Song, L., Gao, X., et al. (2023) · Blood · doi:10.1182/blood.2023020142 · Cited by 56 · see citing works

Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib

Gángó, A., Alpár, D., Galik, B., Marosvári, D., Kiss, R., Fésüs, V., Aczél, D., Eyüpoglu, E., Nagy, N., Nagy, Á., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32502 · Cited by 54 · see citing works

First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma

Woyach, J. A., Stephens, D. M., Flinn, I. W., Bhat, S. A., Savage, R. E., Chai, F., Eathiraj, S., Reiff, S. D., Muhowski, E. M., Granlund, L., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0670 · Cited by 52 · see citing works

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib

Woyach, J. A., Jones, D., Jurczak, W. J., Robak, T., Illés, Á., Kater, A. P., Ghia, P., Byrd, J. C., Seymour, J. F., Long, S., et al. (2024) · Blood · doi:10.1182/blood.2023023659 · Cited by 52 · see citing works

Structural insights and activating mutations in diverse pathologies define mechanisms of deregulation for phospholipase C gamma enzymes

Liu, Y., Bunney, T. D., Khosa, S., Macé, K., Beckenbauer, K., Askwith, T., Maslen, S., Stubbs, C., de Oliveira, T. M., Sader, K., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.102607 · Cited by 42 · see citing works

Single-cell RNA-seq reveals the immune escape and drug resistance mechanisms of mantle cell lymphoma

Wang, L., Mo, S., Li, X., He, Y., & Yang, H. J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0073 · Cited by 41 · see citing works

The potential of pirtobrutinib in multiple B-cell malignancies

Jensen, J. L., Mato, A. R., Peña, C., Roeker, L. E., & Coombs, C. C. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221101697 · Cited by 39 · see citing works

Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance

Fürstenau, M., & Eichhorst, B. F. (2021) · Cancers · doi:10.3390/cancers13061336 · Cited by 37 · see citing works

Noncatalytic Bruton's tyrosine kinase activates PLCγ2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells

Wist, M., Meier, L., Gutman, O., Haas, J., Endres, S., Zhou, Y., Rösler, R., Wiese, S., Stilgenbauer, S., Hobeika, E., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011946 · Cited by 34 · see citing works

Frequent and Persistent PLCG1 Mutations in Sézary Cells Directly Enhance PLCγ1 Activity and Stimulate NFκB, AP-1, and NFAT Signaling

Patel, V. M., Flanagan, C. E., Martins, M., Jones, C. L., Butler, R. M., Woollard, W. J., Bakr, F. S., Yoxall, A., Begum, N., Katan, M., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.07.693 · Cited by 31 · see citing works

Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL)

Chirino, A., Montoya, S., Safronenka, A., & Taylor, J. (2023) · Genes · doi:10.3390/genes14122182 · Cited by 30 · see citing works

Towards precision medicine in lymphoid malignancies

Bühler, M. M., Martín-Subero, J. I., Pan‐Hammarström, Q., Campo, E., & Rosenquist, R. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13423 · Cited by 27 · see citing works

Phospholipase Cγ2 regulates endocannabinoid and eicosanoid networks in innate immune cells

Jing, H., Reed, A., Ulanovskaya, O. A., Grigoleit, J.-S., Herbst, D. M., Henry, C. L., Li, H., Barbas, S., Germain, J., Masuda, K., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2112971118 · Cited by 24 · see citing works

Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling

Li, W., Sano, R., Apatira, M., DeAnda, F., Gururaja, T. L., Yang, M., Lundgaard, G. L., Pan, C., Liu, J., Zhai, Y., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0642 · Cited by 22 · see citing works

Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective

Kwok, M., & Wu, C. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.790004 · Cited by 20 · see citing works

PLCγ2 impacts microglia-related effectors revealing variants and pathways important in Alzheimer’s disease

Li, K., Ran, B., Wang, Y., Liu, L., & Li, W. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.999061 · Cited by 18 · see citing works

Precision diagnostics in lymphomas – Recent developments and future directions

Mansouri, L., Þorvaldsdóttir, B., Laidou, S., Σταματόπουλος, Κ., & Rosenquist, R. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.10.007 · Cited by 17 · see citing works

A Review of Resistance Mechanisms to Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia

Wiśniewski, K., & Puła, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105246 · Cited by 17 · see citing works

Functional characterization of phospholipase C-γ2 mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder

Walliser, C., Wist, M., Hermkes, E., Zhou, Y., Schade, A., Haas, J., Deinzer, J., Désiré, L., Li, S. S. C., Stilgenbauer, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26173 · Cited by 17 · see citing works

Resistance Mechanisms to Targeted Agents in Chronic Lymphocytic Leukemia

Kittai, A. S., & Woyach, J. A. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000406 · Cited by 17 · see citing works

Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies

Bravo-González, A., Alasfour, M., Soong, D., Noy, J., & Pongas, G. N. (2024) · Cancers · doi:10.3390/cancers16203434 · Cited by 14 · see citing works

Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1–derived peptides overcomes drug resistance

Pramil, É., Herbi, L., Denèfle, T., Némati, F., Xiao, M., Lardé, E., Maloum, K., Roos‐Weil, D., Chapiro, É., Garff‐Tavernier, M. L., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000350 · Cited by 13 · see citing works

Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies

Zhou, Y., Kang, J., & Lu, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00361 · Cited by 12 · see citing works

Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton’s Tyrosine Kinase Inhibitors

Thompson, M. C., & Mato, A. R. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.03.008 · Cited by 10 · see citing works

Overcoming Resistance in Chronic Lymphocytic Leukemia—Maybe Less Is More?

Al‐Sawaf, O., & Davids, M. S. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2872 · Cited by 9 · see citing works

Promises and pitfalls of targeted agents in chronic lymphocytic leukemia

Lew, T. E., Anderson, M. A., & Seymour, J. F. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.108 · Cited by 9 · see citing works

Characterisation of molecular mechanisms for PLCγ2 disease-linked variants

Bunney, T. D., Kampyli, C., Gregory, A., & Katan, M. (2024) · Advances in Biological Regulation · doi:10.1016/j.jbior.2024.101053 · Cited by 8 · see citing works

Current and future of targeted therapies against BCR::ABL kinases

Sridhar, J., Subramanian, M., Kesavan, P. K., & Jayavel, S. (2025) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-025-00263-5 · Cited by 8 · see citing works

T Cells Spatially Regulate B Cell Receptor Signaling in Lymphomas through H3K9me3 Modifications

Britto, L. S., Balasubramani, D., Desai, S., Phillips, P., Trehan, N., Cesarman, E., Koff, J. L., & Singh, A. K. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401192 · Cited by 8 · see citing works

Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia

Albi, E., Capasso, A., Schiattone, L., Ghia, P., & Scarfò, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.01.009 · Cited by 8 · see citing works

Survival analysis of genome-wide profiles coupled with Connectivity Map database mining to identify potential therapeutic targets for cholangiocarcinoma

Lin, P., Zhong, X., Wang, X., Li, J., Zhao, R., He, Y., Jiang, Y., Xian-wen, H., Chen, G., He, Y., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6710 · Cited by 8 · see citing works

The crystal and cryo-EM structures of PLCγ2 reveal dynamic interdomain recognitions in autoinhibition

Shin, Y.-C., Plummer-Medeiros, A. M., Mungenast, A., Choi, H.-W., TenDyke, K., Zhu, X., Shepard, J., Sanders, K., Zhuang, N., Hu, L., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn6037 · Cited by 7 · see citing works

Research progress on gene mutations and drug resistance in leukemia

Ma, X., Xu, J., Wang, Y., Fleishman, J. S., Bing, H., Yu, B., Li, Y., Bo, L., Zhang, S., Chen, Z., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101195 · Cited by 7 · see citing works

LC-FACSeq is a method for detecting rare clones in leukemia

Hu, E. Y., Blachly, J. S., Saygin, C., Özer, H. G., Workman, S. E., Lozanski, A., Doong, T.-J., Chiang, C., Bhat, S. A., Rogers, K. A., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.134973 · Cited by 6 · see citing works

Monitoring Response and Resistance to Treatment in Chronic Lymphocytic Leukemia

Giudice, I. D., Starza, I. D., Falco, F. D., Gaïdano, G., & Sportoletti, P. (2024) · Cancers · doi:10.3390/cancers16112049 · Cited by 5 · see citing works

Genomics of Resistance to Targeted Therapies

Thangavadivel, S., & Woyach, J. A. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.03.004 · Cited by 3 · see citing works

Successful treatment of second-time CAR-T 19 therapy after failure of first-time CAR-T 19 and ibrutinib therapy in relapsed mantle cell lymphoma

Mu, J., Liu, M., Wang, J., Meng, J., Zhang, R., Jiang, Y., & Deng, Q. (2022) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/145948 · Cited by 3 · see citing works

Chronic Lymphocytic Leukemia: Who, How, and Where?

Scarfò, L., & Ghia, P. (2019) · Hematologic malignancies · doi:10.1007/978-3-030-11392-6_1 · Cited by 3 · see citing works

Targeting of ibrutinib resistance–driving pathways by miR-28 in ABC-DLBCL

Álvarez-Corrales, E., Moreno-Palomares, R., Gómez‐Escolar, C., Martínez‐Mingo, M., Moral-Pérez, U., Laguna-Herrero, M., Fuertes, T., Estrada, B. S., Mur, S. M., de Bonis, A., et al. (2026) · Leukemia · doi:10.1038/s41375-026-02948-9 · Cited by 2 · see citing works

Novel isolated mutations at the C515 residue of BTK in a CLL patient associated with acalabrutinib resistance

Dimou, M., Karypidou, M., Bitsani, A., Belia, M., Kopsaftopoulou, A., Zerzi, K., Kiriakopoulos, A., Sachanas, S. P., Pessach, I., Kolotsiou, A., et al. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2501269 · Cited by 2 · see citing works

A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia

Raghunathan, V. M., Fan, G., Kittai, A. S., Okada, C. Y., Danilov, A. V., & Spurgeon, S. E. F. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13538 · Cited by 2 · see citing works

Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study

Rogers, K. A., Yan, P. S., Flinn, I. W., Stephens, D. M., Kipps, T. J., Larson, S. M., Martz, L., Chen, X., Wang, H., Hopping, E., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0210 · Cited by 1 · see citing works

Computational hybrid framework integrating clinical-mutation profiling and physics-based simulations to predict structural tolerance of Bruton tyrosine kinase (BTK) and sustained ARQ 531 binding

Khan, A., Sawali, M. A., Shkoor, M., Hasssan, F., Al-Zoubi, R. M., Alshabrmi, F. M., Crovella, S., & Agouni, A. (2026) · Current Research in Structural Biology · doi:10.1016/j.crstbi.2026.100186 · Cited by 1 · see citing works

Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib

Mauro, F. R., & Foà, R. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30910-5 · Cited by 1 · see citing works

Evaluation of the relative allelic load of mutations of resistance to ibrutinib in the BTK gene by allele-specific PCR in patients with progression of CLL

Likold, E. B., Вениаминовна, Б. Б., Февралева, И. С., Severina, N. A., Dmitrieva, E. A., Petrenko, A. A., Nikitin, E. A., & Sudarikov, A. B. (2023) · Гематология и трансфузиология · doi:10.35754/0234-5730-2023-68-2-182-194 · Cited by 1 · see citing works

Mechanisms of resistance to targeted therapies in chronic lymphocytic leukemia

Sutton, L. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000240 · Cited by 1 · see citing works

BTK Inhibitors: Focus on Ibrutinib and Similar Agents

Mattsson, M., & Scarfò, L. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-75184-9_1

Resistance to targeted therapy in chronic lymphocytic leukemia

Milošević, I. (2022) · Medicinski pregled · doi:10.2298/mpns22s1057m

Single nucleotide polymorphisms conferring susceptibility to leukemia and oral mucositis: a multi-center pilot study of patients prior to conditioning therapy for hematopoietic cell transplant

Mougeot, J.-L., Beckman, M. F., Alexander, A. S., Hovan, A. J., Hasséus, B., Legert, K. G., Johansson, J., Bültzingslöwen, I. V., Brennan, M. T., & Mougeot, F. B. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08408-3

Navigating the Paradigm Shift in Chronic Lymphocytic Leukemia Treatment from Chemotherapy to Targeted Therapies

Phua, C. W. W., & Lam, S. (2024) · Canadian Hematology Today · doi:10.58931/cht.2024.3s01-244

1206 Next-Generation Sequencing for Lymphoid Neoplasms: Real-World Utility from a Clinical Assay

Chen, C., Artymiuk, C. J., Schwab, T. L., Feldman, A. L., Jevremović, D., McPhail, E. D., Rech, K. L., Viswanatha, D. S., Hampel, P. J., Wang, Y., et al. (2025) · Human Pathology · doi:10.1016/j.humpath.2026.106123

Optimisation de peptides agonistes du récepteur CD47 : induction d'un nouveau type de mort cellulaire programmée contre les formes réfractaires de leucémie lymphoïde chronique

Pramil, É. (2019) · theses.fr (ABES) · doi:10.70675/0e14246dz2663z4751z9df2zdbd3c05619fb

Analyse des sous-populations lymphocytaires B dans la leucémie lymphoïde chronique et de l'Impact de l'ibrutinib sur ces sous-populations

Quinquenel, A. (2018) · doi:10.70675/ec796fc6z7f70z4097za519z0989f82071f7

Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study

Liao, P., Ko, B., Su, Y., Chao, W., & Teng, C. J. (2026) · Cancer Medicine · doi:10.1002/cam4.72022

BindingDB Entry 50022072: Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies.

BindingDB (2025) · UC San Diego · doi:10.7270/q21n85tb

Abstract 3150: PLCG2 C2-domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing treatment with the BTK inhibitor ibrutinib

Jones, D. M., Woyach, J. A., Zhao, W., Caruthers, S., Tu, H., Coleman, J. F., Byrd, J. C., Johnson, A. J., & Lozanski, G. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-3150 · Cited by 1 · see citing works

AreBTKandPLCG2mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?

Lampson, B. L., & Brown, J. R. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1435268 · Cited by 74 · see citing works

PB1912: BTK AND PLCG2 GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH RESISTANCE TO COVALENT BTK INHIBITOR

Likold, E. B., Вениаминовна, Б. Б., Dmitrieva, E. A., Smirnova, S., Kislova, M. I., Nikitin, E. A., & Sudarikov, A. B. (2023) · HemaSphere · doi:10.1097/01.hs9.0000974472.89677.37 · Cited by 1 · see citing works

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

Bonfiglio, S., Sutton, L., Ljungström, V., Capasso, A., Pandzic, T., Weström, S., Asl, H. F., Skaftason, A., Gellerbring, A., Lyander, A., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008821 · Cited by 74 · see citing works

A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia

Raghunathan, V. M., Fan, G., Kittai, A. S., Okada, C. Y., Danilov, A. V., & Spurgeon, S. E. F. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13538 · Cited by 2 · see citing works